A novel PET imaging approach has revealed distinct patterns of brain inflammation in patients with progressive apraxia of speech (PAOS), a rare neurodegenerative disorder that affects speech planning. These findings provide new insight into how neuroinflammation and tau pathology may drive disease progression in PAOS, opening potential avenues for earlier diagnosis and targeted treatments.

This research was presented at the Society of Nuclear Medicine and Molecular Imaging 2025 Annual Meeting and published as a supplement in the Journal of Nuclear Medicine.

PAOS is a neurodegenerative disorder that impairs the brain’s ability to plan and coordinate speech. It is marked by a slow speaking rate, distorted sounds, and effortful facial movements during speech. Patients with PAOS are likely to have Parkinson-plus syndrome in the later stages, meeting criteria for progressive supranuclear palsy or corticobasal syndrome, and typically have a 4-repeat tauopathy at autopsy.

A drug called lenacapavir, administered in two injections a year, offers protection from HIV comparable to daily pills. One looming question: Will it be affordable for lower resource countries?

Task-evoked dorsal attention network activity and AD pathology influence memory formation in cognitively unimpaired older adults.

Noetik will use its multimodal AI models to identify which patients will most likely benefit from Agenus’s lead immuno-oncology combination, BOT/BAL.

CLNS1A promotes autoimmunity through epigenetic and transcriptional regulation of DNA repair and cell cycle progression in CD4 T cells.

Insulin resistance detected by routine triglyceride-glucose (TyG) index can flag people with early Alzheimer’s who are four times more likely to present rapid cognitive decline, according to new research presented at the European Academy of Neurology (EAN) Congress 2025.

Neurologists at the University of Brescia reviewed records of 315 non-diabetic patients with cognitive deficits, including 200 with biologically confirmed Alzheimer’s disease. All subjects underwent an assessment of insulin resistance using the TyG index and a clinical follow-up of three years.

The work is published in the journal Alzheimer’s & Dementia.

Researchers at the Max Planck Institute for Molecular Genetics have developed a novel synthetic micropeptide termed the “killswitch” to selectively immobilize proteins within cellular condensates, unveiling crucial connections between condensate microenvironments and their biological functions.

Biomolecular condensates are specialized regions inside cells, existing without membranes, where critical biochemical reactions occur. Their importance in health and disease is well established, including roles in cancer progression and viral infection.

Methods to precisely probe and manipulate condensates in living cells remain limited. Existing strategies lack specificity, either dissolving condensates indiscriminately or requiring artificial protein overexpression, which obscures the natural behavior of native cellular proteins.

Early childhood caries (ECC)—the world’s most prevalent chronic childhood disease—disproportionately targets specific teeth, a mystery that has remained unresolved until now.

A collaborative research team from the Faculty of Dentistry of the University of Hong Kong (HKU), Chinese Academy of Sciences (CAS-QIBEBT), Qingdao Stomatological Hospital, and Qingdao Women and Children’s Hospital has made a discovery that could revolutionize the prevention of childhood tooth decay.

The team has developed the world’s first artificial intelligence (AI) system capable of predicting early childhood caries risk for individual teeth based on microbial characteristics, achieving an accuracy rate of more than 90%. The study is published in Cell Host & Microbe.

Penn-led researchers have turned a deadly fungus into a potent cancer-fighting compound. After isolating a new class of molecules from Aspergillus flavus, a toxic crop fungus linked to deaths in the excavations of ancient tombs, the researchers modified the chemicals and tested them against leukemia cells. The result? A promising cancer-killing compound that rivals FDA-approved drugs and opens up new frontiers in the discovery of more fungal medicines.

“Fungi gave us penicillin,” says Sherry Gao, Presidential Penn Compact Associate Professor in Chemical and Biomolecular Engineering (CBE) and in Bioengineering (BE) and senior author of a new paper in Nature Chemical Biology on the findings. “These results show that many more medicines derived from natural products remain to be found.”

Most treatments for Parkinson’s disease (PD) only slow disease progression. Early intervention for the neurological disease that worsens over time is therefore critical to optimize care, but that requires early diagnosis. Current tests, like clinical rating scales and neural imaging, can be subjective and costly. Now, researchers in ACS’ Analytical Chemistry report the initial development of a system that inexpensively screens for PD from the odors in a person’s earwax.

Previous research has shown that changes in sebum, an oily substance secreted by the skin, could help identify people with PD. Specifically, sebum from people with PD may have a characteristic smell because volatile organic compounds (VOCs) released by sebum are altered by disease progression — including neurodegeneration, systemic inflammation and oxidative stress.

However, when sebum on the skin is exposed to environmental factors like air pollution and humidity, its composition can be altered, making it an unreliable testing medium. But the skin inside the ear canal is kept away from the elements. So, Hao Dong, Danhua Zhu and colleagues wanted to focus their PD screening efforts on earwax, which mostly consists of sebum and is easily sampled.